IBD-PSC.
Plain-language, evidence-based information about IBD with primary sclerosing cholangitis — the distinct colitis, cancer surveillance, liver disease, and pouch surgery, and why this combination is followed differently from IBD alone.
Right-sided colitis
Backwash ileitis
Rectal sparing
Colorectal-cancer risk
PSC — biliary strictures
The distinct colitis
The bowel inflammation in IBD-PSC often looks different from ordinary ulcerative colitis — extensive yet mild, right-sided, with rectal sparing and backwash ileitis — and it carries a markedly higher colorectal-cancer risk. 1–3
| Feature | UC | PSC-IBD | Crohn's |
|---|---|---|---|
| Pattern | |||
| Extent | Variable | Extensive / pancolitis | Segmental |
| Distribution | Left-sided | Right-sided | Patchy / skips |
| Rectum | Involved | Often spared | Often spared |
| Backwash ileitis | Sometimes | Common | Crohn's ileitis |
| Disease activity | Symptomatic | Mild / often quiescent | Symptomatic |
| Risk | |||
| Colorectal cancer | Increased | Markedly increased | Increased |
| Pouchitis after IPAA | Baseline | Higher, chronic | Uncommon |
Despite being extensive, PSC-IBD colitis is often mild or silent — which is exactly why annual surveillance colonoscopy begins at PSC diagnosis: the colorectal-cancer risk is markedly higher, especially in the right colon. Backwash ileitis: mild inflammation of the last part of the small bowel spilling back from an inflamed cecum. 6–8
Top topics in the research
The twelve most-studied themes in the IBD-PSC research library behind this site, and how publishing on each has grown (1980–2026). Topics overlap, so these counts do not sum to the library total.
Frequently Asked Questions
Quick, plain-language answers to the questions we hear most.
What is IBD-PSC?
IBD-PSC is the overlap of inflammatory bowel disease (most often ulcerative colitis, sometimes Crohn's colitis) with primary sclerosing cholangitis (PSC), a chronic disease that inflames and scars the bile ducts. Most people with PSC also have IBD, and the combination behaves differently from IBD alone. 1,3
What is PSC (primary sclerosing cholangitis)?
Primary sclerosing cholangitis (PSC) is a chronic liver disease in which the bile ducts inside and outside the liver become inflamed and scarred, narrowing them and slowing bile flow. Over years this can progress to liver damage. PSC is strongly linked to inflammatory bowel disease, raises the risk of bile-duct and colorectal cancer, and is followed by a hepatologist; advanced PSC may ultimately need a liver transplant. 14,15
How are IBD and PSC connected — and how common is each?
They frequently occur together: roughly 70% of people with PSC also have IBD, while PSC develops in only a small minority of people with ulcerative colitis. The colitis of IBD-PSC tends to be extensive but mild, often with rectal sparing and backwash ileitis. 1,4,5
Why does the IBD-PSC label matter?
IBD-PSC is its own phenotype with specific risks — especially a substantially higher chance of colorectal cancer — so surveillance and management differ from ordinary IBD. Recognizing the combination is what triggers earlier, more intensive monitoring. 2,6
Who should manage IBD-PSC?
It is best managed as a shared-care condition by a team — gastroenterology and hepatology for the bowel and liver, and colorectal surgery when surgery is needed. Care is coordinated because decisions about the colon, the liver, and any transplant affect one another. 14,16
Why is cancer surveillance so important in IBD-PSC?
IBD-PSC carries a substantially higher risk of colorectal cancer than IBD without PSC, and it tends to arise in the right colon. Guidelines recommend annual surveillance colonoscopy starting at the time of PSC diagnosis — earlier and more often than in IBD alone. 6–10
How does PSC change cancer surveillance and risk in IBD?
PSC is one of the strongest risk multipliers for colorectal cancer in IBD. Guidelines recommend annual colonoscopic surveillance from the time of PSC diagnosis — not the usual 8-to-10-year interval — and the risk persists even after a J-pouch, so pouch surveillance continues too. PSC also raises bile-duct cancer risk and can progress to liver transplant, which interacts with the timing of colorectal surgery.
Does the cancer risk include the bile ducts?
Yes. Beyond the colon, PSC raises the risk of bile-duct cancer (cholangiocarcinoma) and gallbladder cancer, which the liver team monitors separately with imaging and blood tests. 11–13
Will I need a liver transplant?
Not everyone does, but PSC can slowly progress to advanced liver disease over years, and liver transplantation is the most effective treatment for end-stage PSC. Many people live for a long time with PSC before transplant is considered, and care is shared with a hepatologist. 19–21
Can I have J-pouch surgery if I have IBD-PSC?
Yes. People with IBD-PSC who need surgery for ulcerative colitis can undergo ileal pouch-anal anastomosis (IPAA). Pouch outcomes are generally acceptable, though chronic pouchitis is more common in PSC. Timing relative to the liver disease and any transplant is individualized by the surgical and liver teams. 24,28
The Distinct Colitis of IBD-PSC
The bowel inflammation in IBD-PSC often looks different from typical ulcerative colitis — and knowing the pattern changes how it is watched. It tends to be widespread yet mild, favors the right side of the colon, and can spare the rectum. 1–5
Extensive but often mild
The inflammation frequently involves the whole colon, yet day-to-day symptoms can be milder than expected — sometimes almost silent. 2,3
Rectal sparing & backwash ileitis
The rectum may be relatively spared (unlike most ulcerative colitis), and inflammation can extend back into the end of the small intestine. 1,3
IBD-PSC carries a substantially higher colorectal-cancer risk than IBD without PSC. Guidelines recommend yearly surveillance colonoscopy beginning at the time of PSC diagnosis — earlier and more often than in IBD alone. Keeping up with these scopes is the single most protective thing you can do. 6–10
Colorectal cancer
Higher risk and earlier onset — hence annual surveillance with chromoendoscopy or high-definition colonoscopy and targeted biopsies. 6,9
Bile-duct & gallbladder cancer
PSC also raises the risk of cholangiocarcinoma and gallbladder cancer; your liver team monitors these with imaging and blood tests. 11–13
Why surveillance starts at PSC diagnosis, not later Advanced
In IBD without PSC, surveillance colonoscopy usually begins about 8–10 years after diagnosis. In IBD-PSC the cancer risk is high enough — and can appear early enough — that guidelines recommend starting annual surveillance from the moment PSC is diagnosed. 6,7
Because the neoplasia tends to be right-sided and can arise in flat, hard-to-see mucosa, high-definition or dye-spray (chromoendoscopy) technique with targeted biopsies is preferred. 8,10
The Liver & Transplant
PSC is a slowly progressive disease of the bile ducts, followed closely by a hepatologist over many years. It is monitored, its symptoms are treatable, and for advanced disease, transplantation is highly effective. 14,15
Monitoring
Liver blood tests and MRCP imaging track the bile ducts over time to catch strictures and complications early. 16,17
Symptoms
Itching, fatigue, and episodes of bile-duct infection (cholangitis) can occur and are treatable — tell your team promptly. 18
Transplant
For advanced PSC, liver transplantation is the most effective treatment; many people live well for years before it is needed. 19–21
PSC can recur after transplant Advanced
PSC can come back in the transplanted liver (recurrent PSC) in a minority of people, which is why hepatology follow-up and monitoring continue lifelong after transplant. 19
Dominant bile-duct strictures are also watched carefully, since they can signal complications — including a small risk of bile-duct cancer — and are often managed endoscopically. 20,21
Surgery & the J-Pouch
When the colitis needs surgery, people with IBD-PSC can still have restorative pouch surgery — with a few PSC-specific considerations around pouchitis, timing, and ongoing surveillance. 24–26
IPAA (J-pouch) is an option
Ileal pouch-anal anastomosis is feasible in IBD-PSC, and function is generally good. 24,27
More pouchitis
Chronic pouchitis is more common in PSC and is managed medically; it rarely means the pouch has failed. 28,29
Timing matters
Surgery is coordinated with the liver disease and any planned transplant, so the teams plan it together. 25,30
Surveillance continues
Even after pouch surgery, monitoring of the pouch and cuff remains important — the cancer risk is lowered, not erased. 26
Pouch vs permanent ileostomy in PSC Advanced
Most people who need surgery for the colitis can have a J-pouch. In selected cases — especially where the liver disease is advanced — a permanent end ileostomy is discussed, and some data suggest colectomy patterns interact with liver-disease progression. These are individualized, team-based decisions. 28,30
For patient-friendly detail on J-pouch (IPAA) surgery and daily life, see pouchy.org; for the research literature, pouchology.org; and for the surgical evidence hub, crohnsology.org.
Risk Calculators & Guidelines
The published guidelines for IBD-PSC lean on a handful of validated risk models — the AASLD and EASL documents both point to them by name. This page gathers the calculators themselves alongside the guidelines that recommend them, so the tool and the recommendation sit side by side.
For clinicians. These are prognostic and allocation tools used by hepatology, GI, and surgical teams. They estimate risk at a population level — they do not diagnose, and no score should be read as a prediction about any one person. If you have PSC, bring a result to your own team rather than interpreting it alone.
How the liver disease is scored
Each of these predicts transplant-free survival or decompensation from routine labs. They differ in what they were trained on and how far ahead they look.
Revised Mayo PSC Risk Score
The long-standing benchmark. Age, bilirubin, AST, albumin, and history of variceal bleeding — no liver biopsy needed. Predicts survival probability out to 4 years.
MDCalc version · Kim WR, et al. Mayo Clin Proc 2000;75(7):688–694. PMID 10907383
PREsTo
PSC Risk Estimate Tool — a machine-learning model using nine routine variables to predict hepatic decompensation at 5 years. Outperformed both MELD and the Mayo score in validation (C-statistic 0.90).
Eaton JE, et al. Hepatology 2020;71(1):214–224. PMID 29742811
UK-PSC risk scores
Two scores from a cohort of over 1,000 UK patients: a short-term score at diagnosis predicting 2-year transplant-free survival, and a long-term score at 2 years predicting 10-year survival.
Patient-facing explainer (PSC Support) · Goode EC, et al. Hepatology 2019;69(5):2120–2135. PMID 30566748
Amsterdam-Oxford Model
Built on a largely population-based Dutch cohort and validated in the UK. Uses age at diagnosis, PSC subtype (large- vs small-duct), albumin, ALP, AST, bilirubin, and platelets. No official hosted calculator — the equation is published in full.
de Vries EMG, et al. Gut 2018;67(10):1864–1869. PMID 28739581
Enhanced Liver Fibrosis (ELF) score
A serum fibrosis panel, not a formula you compute yourself — it is ordered as a lab test. Predicts transplant-free survival in PSC and adds prognostic information beyond the clinical scores above.
Vesterhus M, et al. Hepatology 2015;62(1):188–197. PMID 25833813
Liver allocation
MELD is what determines position on the US transplant waiting list — a different question from the prognostic scores above, which describe the disease rather than the queue.
MELD 3.0
The current US allocation standard since 2023. Adds female sex and serum albumin to the older MELD-Na, with a lower creatinine ceiling.
MDCalc (MELD 3.0, MELD-Na, original MELD) · Kim WR, et al. Gastroenterology 2021;161(6):1887–1895. PMID 34481845
Why MELD under-reads PSC
MELD captures synthetic liver failure. It does not capture recurrent cholangitis, intractable itch, or dominant strictures — the complications that often drive the need for transplant in PSC. This is the rationale for exception points, and it is discussed in both the AASLD and EASL documents below.
Compare transplant centers (SRTR)
The Scientific Registry of Transplant Recipients publishes program-specific outcomes for every US liver transplant program — waitlist time, transplant rate, and graft and patient survival, each reported against what would be expected for that program’s case mix. Updated every January and July.
National transplant data (UNOS / OPTN)
System-level trends rather than center-level scorecards — how many liver transplants are done, waitlist size, and how allocation is changing over time.
Read a center report alongside the guidelines, not instead of them: an expected-vs-observed figure describes a program’s whole population, and PSC is a small and atypical slice of it.
Colorectal surveillance risk
There is no validated, publicly hosted calculator for colorectal cancer risk in IBD-PSC. Surveillance is interval-based, and PSC itself is the risk factor that sets the interval.
What the guidelines say instead of a score
PSC moves a person straight to the shortest surveillance interval — annual colonoscopy from the time of PSC diagnosis, regardless of how long the colitis has been present or how mild it looks. That recommendation is common to the AASLD, EASL, ACG, and AGA documents below.
Dynamic prediction of advanced neoplasia
A research model that updates risk as surveillance findings accumulate over time, rather than fixing it at diagnosis. Not yet a bedside tool, but the direction the field is moving.
Wijnands AM, et al. Clin Gastroenterol Hepatol 2024;22(8):1697–1708. PMID 38431223
PSC and the liver
AASLD Practice Guidance on PSC and cholangiocarcinoma (2022)
The current US reference. Covers diagnosis, MRCP surveillance, dominant strictures, hepatobiliary cancer surveillance, transplant, and the IBD-PSC colon — and names the prognostic models above.
Bowlus CL, et al. Hepatology 2023;77(2):659–702. Full text · PMID 36083140
EASL Clinical Practice Guidelines on sclerosing cholangitis (2022)
The European counterpart, published the same year. Graded recommendations across diagnosis, medical therapy, cancer surveillance, and transplantation.
European Association for the Study of the Liver. J Hepatol 2022;77(3):761–806. Full text · PMID 35738507
BSG and UK-PSC guidelines (2019)
The UK guideline, from the same group behind the UK-PSC risk scores.
Chapman MH, et al. Gut 2019;68(8):1356–1378. PMID 31154395
ACG Clinical Guideline: Primary Sclerosing Cholangitis (2015)
Older, but still the ACG's formal statement and widely cited.
Lindor KD, et al. Am J Gastroenterol 2015;110(5):646–659. PMID 25869391
Japan Biliary Association clinical guidelines for PSC (2017)
Sixteen Delphi-derived recommendations with diagnostic and therapeutic flowcharts. Worth reading alongside the Western documents — PSC in Japan has a different age distribution and a markedly lower rate of associated IBD, so the guidance is not simply a translation of AASLD or EASL.
Isayama H, et al. J Gastroenterol 2018;53(9):1006–1034. PMID 29951926
AGA Clinical Practice Update: hepatobiliary cancer surveillance in PSC (2019)
Focused guidance on screening for cholangiocarcinoma and gallbladder cancer — imaging modality, interval, and what to do with a suspicious finding.
Bowlus CL, et al. Clin Gastroenterol Hepatol 2019;17(12):2416–2422. PMID 31306801
The colitis, surveillance, and surgery
ACG Clinical Guideline: Ulcerative Colitis in Adults (2019)
Medical management of the colitis, with PSC called out as a distinct surveillance situation.
Rubin DT, et al. Am J Gastroenterol 2019;114(3):384–413. PMID 30840605
ASCRS Clinical Practice Guidelines: Surgical Management of Ulcerative Colitis (2021)
The surgical guideline — indications, staging, and pouch decisions, including in PSC.
Holubar SD, et al. Dis Colon Rectum 2021;64(7):783–804. PMID 33853087
AGA Clinical Practice Update: endoscopic surveillance and management of colorectal dysplasia in IBD (2021)
Practical guidance on how surveillance colonoscopy should be done and what to do with dysplasia once found.
Murthy SK, et al. Gastroenterology 2021;161(3):1043–1051. PMID 34416977
SCENIC international consensus on dysplasia in IBD (2015)
The consensus that reframed dysplasia terminology and endorsed chromoendoscopy — still the vocabulary the field uses.
Laine L, et al. Gastrointest Endosc 2015;81(3):489–501. PMID 25708752
ECCO Guidelines on Extraintestinal Manifestations in IBD (2024)
Places PSC within the broader set of extraintestinal manifestations and sets out how it should be managed alongside the bowel disease.
Gordon H, et al. J Crohns Colitis 2024;18(1):1–37. PMID 37351850
Where the guidelines disagree Advanced
The two 2022 documents agree on far more than they differ on, but the gaps are worth knowing. Ursodeoxycholic acid is the clearest: neither recommends it routinely, and both note the harm signal at high dose — yet practice varies widely. Cholangiocarcinoma surveillance intervals and the role of ERCP in a dominant stricture are stated with different degrees of confidence. And the timing of colectomy relative to transplant is addressed only in general terms by both, which is precisely the decision an IBD-PSC patient faces.
For the surgical side of that decision, see Surgery & the J-Pouch; for the underlying literature, References.
Explore the IBD-PSC Research
About IBDpsc.org
IBDpsc.org is a plain-language, evidence-based guide to IBD with primary sclerosing cholangitis (IBD-PSC) — the distinct colitis it causes, its heightened cancer-surveillance needs, the liver disease, and pouch surgery. IBD-PSC is uncommon and under-explained, and the research that could inform care often takes ~17 years to reach the clinic; IBDpsc narrows that gap by pairing the newest IBD-PSC literature with a “deep and narrow” AI you can query in plain language. It is part of the IBDology family of paired provider and patient IBD sites.
This site was created by Stefan D. Holubar, MD, MS, FACS, FASCRS, Professor of Surgery at Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine & Case Western Reserve University. A fellowship-trained colorectal surgeon who specializes in inflammatory bowel disease—and, living with IBD and a J-pouch himself, a patient too—he brings both perspectives to this work. He is also a clinician-informatician who designs and builds the AI and decision-support tools behind these sites—from clinical risk calculators and an AI interface to the pouch literature to this hub itself. He is co-PI of the Crohn's & Colitis Foundation IBD-SIRCQ and the ACS-NSQIP IBD Collaborative, founder of the iPouch Consortium, and has authored over 300 peer-reviewed publications.
Dr. Holubar is an employee of Cleveland Clinic, and has the following disclosures: research funding from the American Society of Colon & Rectal Surgeons and the Crohn's & Colitis Foundation, and has no other disclosures or conflicts of interest.